CanSino Biologics’ Meningococcal Conjugate Vaccine Receives Halal Certification

TEDA-based CanSino Biologics Inc. recently announced that its ACYW135 quadrivalent meningococcal polysaccharide conjugate vaccine, Menhycia®, has received Halal certification from the Food, Drug, and Cosmetics Assessment Institute of the Indonesian Ulema Council. This certification marks a significant milestone in the company’s expansion into international markets. Menhycia® is indicated for infants and young children aged 3 months to 3 years (47 months) and provides effective protection against epidemic cerebrospinal meningitis caused by Neisseria meningitidis serogroups ACYW135. Clinical trials conducted in China have demonstrated its strong safety profile and immunogenicity. Currently, CanSino Biologics is conducting clinical trials in Indonesia to assess the vaccine’s safety and immunogenicity in individuals aged 18 to 55.

Founded in 2009 in TEDA, CanSino Biologics is committed to providing innovative solutions for the prevention and treatment of infectious diseases worldwide. The company has established five cutting-edge vaccine platform technologies, including viral vector vaccines, synthetic vaccines, protein structure design and virus-like particle (VLP) assembly, mRNA vaccine technology, and advanced formulation and delivery systems. Its pipeline includes 17 innovative vaccine candidates covering more than 10 indications.